BridgeBio Pharma, Inc. recently announced a US$550,000,000 fixed-rate senior subordinated unsecured notes offering under Rule 144A, while updating investors on advancing late-stage programs and ...
BridgeBio Pharma plans to offer $500 million in convertible senior notes, aiming to strengthen its financial position and reduce interest expenses. BridgeBio Pharma, Inc. announced plans to offer $500 ...
BridgeBio Pharma, Inc. has announced the pricing of $500 million in convertible senior notes at a 1.75% interest rate, maturing in 2031, in a private offering aimed at qualified institutional buyers.
The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium PALO ALTO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results